Related Experiment Videos

Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management

L Joseph Wheat1, Dewey Conces, Stephen D Allen

  • 1MiraVista Diagnostics, Indianapolis, Indiana, USA. jwheat@miravistalabs.com

Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
PubMed

Insights

Histoplasmosis commonly affects the lungs, with diagnosis aided by antibody and antigen tests. Early detection and appropriate antifungal therapy are crucial for severe pulmonary histoplasmosis cases.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Mycology

Background:

  • Pulmonary manifestations are characteristic of histoplasmosis, presenting a spectrum from asymptomatic infection to life-threatening diffuse alveolar disease.
  • Diagnosis often relies on serologic antibody and antigen detection, which are underutilized.
  • Histoplasma capsulatum antigen detection in bronchoalveolar lavage fluid is valuable for acute pulmonary or disseminated disease with lung involvement.

Purpose of the Study:

  • To highlight key considerations for pulmonary disease specialists regarding histoplasmosis.
  • To discuss the differential diagnosis of histoplasmosis in patients with suspected sarcoidosis, lung masses, or mediastinal lymphadenopathy.
  • To review the recognition and management of chronic pulmonary and mediastinal histoplasmosis.

Main Methods:

  • Review of clinical syndromes and diagnostic approaches for pulmonary histoplasmosis.
  • Discussion of therapeutic indications for antifungal agents.
  • Consideration of novel antifungal agents for treatment-resistant cases.

Main Results:

  • Antifungal therapy is recommended for acute diffuse pulmonary infection, chronic pulmonary histoplasmosis, and progressive disseminated disease.
  • Prophylactic antifungal therapy to prevent reactivation or progression of mediastinal adenitis is generally not advised.
  • New antifungal drugs offer alternatives for patients with treatment failure or intolerance.

Conclusions:

  • Pulmonary histoplasmosis requires careful diagnostic consideration and timely management.
  • While often self-limited, specific clinical scenarios necessitate antifungal treatment.
  • Ongoing research into new therapies holds promise for challenging cases.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...